Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan S Berek

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
JCO Global Oncology|September 9, 2025
Randomized Controlled Trial of Impact of Mobile Health Technologies on Human Papillomavirus Vaccination Uptake in Mothers of Vaccine-Eligible Girls in Lagos, Nigeria (mHealth-HPVac)Kehinde Sharafadeen Okunade, Ayomide I Fayinto, Temitope V Adekanye, et al.
JAMA|June 5, 2023
Germline Genetic Testing After Cancer DiagnosisAllison W Kurian, Paul Abrahamse, Allison Furgal, et al.
The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Cancer Research Communications|March 27, 2023
<i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair DefectsMansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, et al.
Annals of Surgical Oncology|July 7, 2011
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selectionWen-Juan Tian, Dennis S Chi, Jalid Sehouli, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancerMadeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology|February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancerFelicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Cell Reports|February 15, 2018
Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass CytometryVeronica D Gonzalez, Nikolay Samusik, Tiffany J Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra, Robert C Bast, Jonathan S Berek, et al.
The Lancet. Oncology|July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trialAmit M Oza, Ursula A Matulonis, Susanne Malander, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
JCO Global Oncology|September 9, 2025
Randomized Controlled Trial of Impact of Mobile Health Technologies on Human Papillomavirus Vaccination Uptake in Mothers of Vaccine-Eligible Girls in Lagos, Nigeria (mHealth-HPVac)Kehinde Sharafadeen Okunade, Ayomide I Fayinto, Temitope V Adekanye, et al.
JAMA|June 5, 2023
Germline Genetic Testing After Cancer DiagnosisAllison W Kurian, Paul Abrahamse, Allison Furgal, et al.
The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Cancer Research Communications|March 27, 2023
<i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair DefectsMansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, et al.
Annals of Surgical Oncology|July 7, 2011
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selectionWen-Juan Tian, Dennis S Chi, Jalid Sehouli, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancerMadeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology|February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancerFelicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Cell Reports|February 15, 2018
Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass CytometryVeronica D Gonzalez, Nikolay Samusik, Tiffany J Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra, Robert C Bast, Jonathan S Berek, et al.
The Lancet. Oncology|July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trialAmit M Oza, Ursula A Matulonis, Susanne Malander, et al.
Pageof 14